Clinuvel Pharmaceuticals Limited Share Price
Stocks
CUV
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.17 AUD | -1.26% |
|
+13.50% | -18.38% |
| 06-16 | Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade | MT |
| 04-28 | Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL | RE |
| Market Cap | 513M 359M 314M 291M 271M 509M 33.97B 3.45B 1.34B 16.7B 1.35B 1.32B 58.03B | P/E 2026 * |
14.3x | P/E 2027 * | 13.4x |
|---|---|---|---|---|---|
| Enterprise Value | 259M 182M 159M 147M 137M 257M 17.17B 1.74B 679M 8.44B 682M 667M 29.32B | EV / Sales 2026 * |
2.61x | EV / Sales 2027 * | 2.15x |
| Free-Float |
83.79% | Yield 2026 * |
0.6% | Yield 2027 * | 0.79% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | -1.26% | ||
| 1 week | +13.50% | ||
| Current month | +11.39% | ||
| 1 month | +10.30% | ||
| 3 months | +5.50% | ||
| 6 months | -23.13% | ||
| Current year | -18.38% |
| 1 week | 9.04 |  | 10.3 |
| 1 month | 8.35 | | 10.3 |
| Current year | 8.35 | | 13.48 |
| 1 year | 8.35 | | 14 |
| 3 years | 8.35 | | 21.45 |
| 5 years | 8.35 | | 44.67 |
| 10 years | 4.1 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 31/10/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 29/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 28/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 22/09/2019 |
| Chairman | - | 31/12/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02/10/24 | Buy | Director | 8,333 | 0.0166% | ||
| 26/11/23 | Fiscal year | Chief Executive Officer | 301,125 | 0.6094% | ||
| 26/11/23 | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.26% | +13.50% | +4.52% | -44.67% | 364M | |
| -0.09% | -1.08% | +18.83% | -21.99% | 62.05B | |
| -0.84% | -4.48% | +50.61% | +196.38% | 54.52B | |
| -5.75% | +29.50% | +29.50% | +29.50% | 41.55B | |
| -2.96% | +4.99% | -53.01% | -60.20% | 39.06B | |
| +0.81% | -0.22% | +58.86% | -32.58% | 29.02B | |
| -6.16% | +15.15% | +133.85% | -50.17% | 25.38B | |
| +4.18% | +0.10% | +51.78% | +64.89% | 19.62B | |
| -1.05% | -1.44% | -3.02% | +139.59% | 16.89B | |
| +1.04% | +2.25% | +60.69% | +111.01% | 15.89B | |
| Average | -1.30% | +3.39% | +35.26% | +33.18% | 30.43B | |
| Weighted average by Cap. | -1.62% | +0.92% | +33.25% | +37.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.46M 69.72M 60.92M 56.35M 52.6M 98.74M 6.59B 670M 261M 3.24B 262M 256M 11.25B | 105M 73.85M 64.53M 59.69M 55.71M 105M 6.98B 709M 276M 3.43B 277M 271M 11.92B |
| Net income | 35.97M 25.21M 22.03M 20.38M 19.02M 35.71M 2.38B 242M 94.22M 1.17B 94.66M 92.6M 4.07B | 38.2M 26.78M 23.4M 21.64M 20.2M 37.92M 2.53B 257M 100M 1.24B 101M 98.35M 4.32B |
| Net Debt | -254M -178M -155M -144M -134M -252M -16.81B -1.71B -665M -8.26B -668M -653M -28.7B | -286M -201M -175M -162M -151M -284M -18.95B -1.93B -749M -9.32B -753M -736M -32.36B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/06/26 | 10.17 $ | -1.26% | 72,231 |
| 19/06/26 | 10.30 $ | +3.73% | 278,606 |
| 18/06/26 | 9.930 $ | +1.53% | 158,140 |
| 17/06/26 | 9.780 $ | +4.60% | 179,394 |
| 16/06/26 | 9.350 $ | +1.08% | 125,614 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
